Alcon Inc. (SWX:ALC)
Market Cap | 40.33B |
Revenue (ttm) | 8.98B |
Net Income (ttm) | 922.49M |
Shares Out | 494.62M |
EPS (ttm) | 1.86 |
PE Ratio | 43.89 |
Forward PE | 28.52 |
Dividend | 0.28 (0.34%) |
Ex-Dividend Date | May 14, 2024 |
Volume | 795,801 |
Average Volume | 1,088,831 |
Open | 82.18 |
Previous Close | 81.76 |
Day's Range | 81.04 - 82.44 |
52-Week Range | 70.90 - 87.00 |
Beta | 0.83 |
RSI | 53.87 |
Earnings Date | Feb 27, 2025 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial numbers in USD Financial StatementsNews
Alcon upgraded at BofA Securities to Buy on earnings growth potential
Alcon Inc (ALC) Launches Clareon Vivity IOL in Europe
Alcon Inc (ALC) Launches Clareon Vivity IOL in Europe

Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
GENEVA--(BUSINESS WIRE)--Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities.
M&A Snapshot: Alcon to acquire LENSAR to boost its cataract equipment portfolio

Alcon Eyes Surgical Edge With LENSAR Buyout: Details
Alcon is set to acquire LENSAR Inc. in a ... Full story available on Benzinga.com
Alcon agrees to acquire LENSAR for $14.00 per share

Alcon Agrees to Acquire LENSAR, Inc.
GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)--Alcon Agrees to Acquire LENSAR, Inc.

Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl Zeiss
Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offerin...

Alcon to Host 2025 Capital Markets Day
GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.

Alcon to Host 2025 Capital Markets Day
GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.
Alcon Stock Gets Relative Strength Rating Lift
A Relative Strength Rating upgrade for Alcon shows improving technical performance. Will it continue?
Alcon Inc (ALC) Expands TOTAL30® for Astigmatism Contact Lens Parameters
Alcon Inc (ALC) Expands TOTAL30® for Astigmatism Contact Lens Parameters

Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters
TORONTO--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the availability of expanded parameters for TOTAL30® for Ast...
Watch CNBC's full interview with Alcon CEO David Endicott
Alcon CEO David Endicott discusses the pharmaceutical firm's full-year results.
Alcon projects $10.2B-$10.4B revenue in 2025 with strong product launches
Alcon Inc. (ALC) Q4 2024 Earnings Call Transcript

Watch CNBC's full interview with Alcon CEO David Endicott
Alcon CEO David Endicott discusses the pharmaceutical firm's full-year results.
Alcon Inc. 2024 Q4 - Results - Earnings Call Presentation

Alcon eyes revenue growth in 2025 after in-line results
Alcon forecast sales of between $10.2 and $10.4 billion for 2025, after the eye care group reported higher fourth-quarter revenue underpinned by its surgical division on Tuesday.
Alcon Inc. Non-GAAP EPS of $0.72 in-line, revenue of $2.48B beats by $10M

Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation
GENEVA--(BUSINESS WIRE)--Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation.
Alcon Inc (ALC) Launches SYSTANE PRO Preservative-Free Eye Drops in the U.S.
Alcon Inc (ALC) Launches SYSTANE PRO Preservative-Free Eye Drops in the U.S.
Alcon Inc. Q4 2024 Earnings Preview

Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet
GENEVA--(BUSINESS WIRE)--Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief with Its Longest Lasting Formula Yet.
Alcon Inc (ALC) Launches Voyager⢠DSLT in the U.S., Revolutionizing Glaucoma Treatment
Alcon Inc (ALC) Launches Voyager⢠DSLT in the U.S., Revolutionizing Glaucoma Treatment